Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ODAC Sides With FDA: Evidence For Elderly AML Drugs Can't Stand On Single-Arm Trials

This article was originally published in The Pink Sheet Daily

Executive Summary

Feasible or not, randomized controlled trials are needed before approval of Genzyme's Clolar and Vion's Onrigin to treat elderly acute myeloid leukemia patients.

You may also be interested in...



Eisai Will Make “Totality Of The Evidence” Argument At FDA Panel Review Of Dacogen

Briefing documents for the Oncologic Drugs Advisory Committee’s Feb. 9 meeting suggest Eisai will argue that the totality of the data on decitabine’s efficacy and safety in elderly patients with acute myelogenous leukemia is sufficient to overcome the pivotal trial’s failure to show a statistically significant overall survival benefit in the primary analysis. In contrast, FDA’s review takes a laser-like focus on the failed primary endpoint.

Cell Therapeutics Boosts Late-Stage Pipeline With Chroma's Tosedostat

Cell Therapeutics to co-develop tosedostat, a potential non-cytotoxic oral therapy for acute myeloid leukemia, with U.K. biotech Chroma Therapeutics.

Cell Therapeutics Boosts Late-Stage Pipeline With Chroma's Tosedostat

Cell Therapeutics to co-develop tosedostat, a potential non-cytotoxic oral therapy for acute myeloid leukemia, with U.K. biotech Chroma Therapeutics.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel